Dr Lal Pathlabs Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Dr Lal Pathlabs Ltd trades at ₹1,909, in a confirmed uptrend and 16 weeks into that stage. That is +16.2% against its own 200-day average. It sits at 96% of a 52-week range of ₹1,308 to ₹1,932. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 10 straight weeks.

Today the stock is in a confirmed uptrend — week 16 of stage 2, confirmed. At ₹1,909 it trades +16.2% versus its 200-day average and sits at 96% of its 52-week range (₹1,308–₹1,932).

Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +343% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 10 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Dr Lal Pathlabs Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: MID_EXPANSION. Our fortnightly research layers last read it on 22 August 2026.

Our read, 22 August 2026. Dr Lal Pathlabs delivered 19.1% Q1 FY27 revenue growth after network expansion, but a 54.3x trailing PE becomes 61.8x on normalized earnings and Q1's 31% OPM is above the 27% normalized level; the setup is fairly priced rather than a trough opportunity.

What is proven. Dr Lal Pathlabs delivered 19.1% Q1 FY27 revenue growth after network expansion, but a 54.3x trailing PE becomes 61.8x on normalized earnings and Q1's 31% OPM is above the 27% normalized level; the setup is fairly priced rather than a trough opportunity.

What is not proven yet. Two consecutive quarters with patient-volume growth below 5.0% YoY and EBITDA margin below 26.0%, or evidence that normalized earnings and capex returns improve enough to make a 61.8x normalized PE materially undervalue the business.

🚨 What would change our mind. Two consecutive quarters with patient-volume growth below 5.0% YoY and EBITDA margin below 26.0%, or evidence that normalized earnings and capex returns improve enough to make a 61.8x normalized PE materially undervalue the business.

Layer 1 read, 22 August 2026 — KEEP. Volumes and revenue accelerating — but a fifth of the price gain expires soon, with no valuation cushion. The June 2026 quarter delivered revenue of Rs 798 Cr, up 19.1%, and profit of Rs 170 Cr, up 26.9%, with 8.2 million patients tested, up 8.2%, and revenue per patient of Rs 968, up 10.0%. Of that 10% realization gain, 2-3 points came from a government-scheme price pass-through that management expects to last only another two to three quarters, and it has put off a general price rise — so the operating margin of 31% is above the 27% level the business normally earns. At Rs 1,894 the shares trade at 56.6x earnings with the modelled margin of safety at minus 56.7%, which means every rupee of return has to be earned by the business and none of it can come from the rating.

What would change Layer 1’s mind. Patient volume growth falling below 5% for two consecutive quarters while the operating margin drops under 26% once the government-scheme pass-through annualizes — that would confirm the June step-up was a pricing window rather than a network effect, and at 56.6x there is no multiple cushion to absorb it. The mirror image would also change my mind in the other direction: revenue per patient still growing above 6% two full quarters AFTER the pass-through ends would prove test-mix and premium…

Layer 2 read, 22 August 2026 — BENCH. Volume growth is real, but today’s margin has an expiry date while competitors keep building. Patient volume reached 8.2 million, up 8.2%, and samples rose 10.7%, which the sector's volume-led Q1 claim confirms. But the 31% margin includes a CGHS/ECHS benefit expected for another two quarters, while sector capex is up 44.84% and CWIP 119.72% with institutions absent.

What would change Layer 2’s mind. Two reported quarters with operating margin at or above 30% after the CGHS/ECHS benefit expires would flip BENCH to ADVANCE because the margin step-up would then be structural rather than temporary.

The test written in advance. Two consecutive quarters with patient-volume growth below 5.0% YoY and EBITDA margin below 26.0%, or evidence that normalized earnings and capex returns improve enough to make a 61.8x normalized PE materially undervalue the business. — the thesis as written as stated by the next result.

The test written in advance. Above-Normal Margin and Fair-Valuation Risk — Above-Normal Margin and Fair-Valuation Risk Two quarters of OPM near or above 30% after the stated pricing benefit expires. by the next result.

The test written in advance. Management Guidance Revisions and Target Consistency — Management Guidance Revisions and Target Consistency Further changes to capex, radiology-center count or full-year margin framing. by the next result.

🚨 What the surface reading misses. The surface reading is: Reported ROE of 22.3%, ROCE of 28.0% and net-cash capacity indicate a profitable diagnostics franchise. The research reads it further: The reported returns coexist with a 31% current OPM that deterministic normalization reduces to 27%; valuation and returns should be assessed on normalized rather than peak-quarter margins.

🚨 What the surface reading misses. The surface reading is: The latest four reported quarters show TTM revenue of Rs 2,892 Cr and PAT of Rs 545 Cr. The research reads it further: The latest 31% OPM matches Sep25 and is above the two intervening 27% quarters; Q1 growth is clear, but margin normalization remains necessary.

Lever 1 · Operating leverage — BUILDING. Q1 FY27 patient volume reached 8.2 million, up 8.2% YoY, after the network additions cited by management. What proves it keeps working: Network Infrastructure Maturation and Patient Volume Acceleration. It stops working if Patient-volume growth falls below 5.0% for two consecutive quarters.

Lever 3 · Management change — BUILDING. CGHS/ECHS contributed 2.0-3.0% to realization and Swasthfit grew around 20.0%, helping revenue per patient reach Rs 968. What proves it keeps working: CGHS/ECHS Realization Pass-Through and Swasthfit Premiumization. It stops working if The CGHS/ECHS benefit annualizes without sustained patient volume or test-mix support.

Lever 2 · Value-added mix — BUILDING. Suburban moved close to double-digit growth after business and LIMS integration. What proves it keeps working: Suburban West Region Rebound and LIMS Integration. It stops working if West-region growth weakens or integration friction returns.

Lever 4 · Paying down debt — BUILDING. The company launched 716 tests and reports routine-test turnaround within three hours for almost 90% of walk-in patients. What proves it keeps working: Digital Automation and Scientific Portfolio Expansion. It stops working if Specialized-test adoption fails to translate into sustained mix or volume.

Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Dr Lal Pathlabs Ltd reported ₹798 Cr of revenue in the Jun 26 quarter, +19.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 13.3% a year. The last full year, FY26, came in at ₹2,763 Cr. The last four reported quarters add to ₹2,892 Cr.

FY26 revenue came in at ₹2,763 Cr (+12.3% on the year), capping 10 years at 13.3% compound. The latest quarter (Jun 26) printed ₹798 Cr, +19.1% year on year — the 12th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +14.3% growth against the decade's 13.3% — the current year is running in line with its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +14.3% over the last 4 quarters against +12.5%/yr over the last 8 — stabilising; TTM profit +5.0% vs +18.7%/yr — rolling over.

FY26-Q4. revenue ₹703 Cr and profit ₹132 Cr as reported.

FY27-Q1. revenue ₹798 Cr and profit ₹170 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Dr Lal Pathlabs Ltd's operating margin is 31.0% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 24.0% to 28.0%. The current quarter is running above every full year in that window.

Why this happened. Patient volume increased 8.2% YoY and samples increased 10.7% to 25.9 million. Management retains a 6-7% starting-year patient-volume view and will reassess after Q2 or H1, so one quarter does not establish a permanent acceleration.

The latest quarter's operating margin is 31.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 24.0%–28.0%, and FY26's 28.0% is the top of that band — a record year.

Why the margin moved: operating margin went +2.3 pp year on year while gross margin went +0.2 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY26-Q4. revenue ₹703 Cr and profit ₹132 Cr as reported.

FY27-Q1. revenue ₹798 Cr and profit ₹170 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Dr Lal Pathlabs Ltd earned ₹170 Cr of net profit in the Jun 26 quarter, +26.9% year on year. Full-year FY26 profit was ₹510 Cr. The 10-year compound rate is 14.4%. That is 21.3% of the quarter's revenue. The same quarter a year earlier earned ₹134 Cr.

Jun 26 profit was ₹170 Cr, +26.9% year on year. On the full year, FY26 printed ₹510 Cr (+3.7%), and the 10-year compound rate is 14.4%.

Why profit moved: revenue contributed +19.1% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +5.1% vs revenue +14.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

FY26-Q4. revenue ₹703 Cr and profit ₹132 Cr as reported.

FY27-Q1. revenue ₹798 Cr and profit ₹170 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 128% of Dr Lal Pathlabs Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹636 Cr of operating cash against ₹510 Cr of profit. After ₹254 Cr of capital spending, ₹382 Cr was left as free cash.

FY26: operating cash of ₹636 Cr against reported profit of ₹510 Cr, leaving free cash of ₹382 Cr after ₹254 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 128% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 128%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Dr Lal Pathlabs Ltd's cash conversion cycle runs −79 days in FY26, down from −78 days in FY21. Capital spending ran ₹401 Cr over the last 3 years. At FY26 sales of ₹2,763 Cr each day of that cycle holds about ₹7.6 Cr, so roughly ₹−598 Cr sits inside the business at any moment.

FY26: debtors at 15 days, inventory at 30 days — roughly 1.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −79 days, tighter than FY21's −78.

The full loop: cash goes out to suppliers and production on day 0; stock waits 30 days to sell; customers pay about 15 days after that; and suppliers themselves are paid at 123 days — netting out to the −79-day cycle.

In money terms: at FY26 sales of ₹2,763 Cr, each day of the cycle holds about ₹7.6 Cr — so the −79-day loop keeps roughly ₹−598 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹401 Cr over the last 3 fiscal years against ₹448 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹7.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Dr Lal Pathlabs Ltd earns a ROCE of 28% in FY26. That is up from a trough of 18% in FY23. Return on invested capital clears the cost of that capital by +24.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 18.5% net margin on 0.88× asset turns.

FY26 ROCE is 28%, recovered from a FY23 trough of 18% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 18.5% net margin × 0.88× asset turns × 1.25× balance-sheet leverage ≈ 20.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 36.3% − 12.0% = a +24.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Dr Lal Pathlabs Ltd carries total debt of ₹199 Cr against shareholder equity of ₹2,541 Cr as of Mar 26, a debt-to-equity of 0.08 — effectively unlevered. On the annual view that ratio went from 0.35 in FY22 to 0.08 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Why this happened. The GenAI WhatsApp bot supports inquiry, booking, location and report access. The company launched 716 tests, including four first-in-India and 81 specialized tests, although the call does not quantify the resulting revenue contribution.

Mar 26: total debt of ₹199 Cr against shareholder equity of ₹2,541 Cr — a debt-to-equity of 0.08. On the annual view, debt-to-equity went from 0.35 (FY22) to 0.08 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 9.2 points of Dr Lal Pathlabs Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 21.6% of the company. Foreign institutions moved −8.1 points over the same window, to 17.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.

Why this happened. Revenue per patient rose 10.0% to Rs 968. CGHS/ECHS pricing accounted for 2.0-3.0% at company level for another two to three quarters, while remaining uplift came from test and geographic mix. Higher-realization tests also carry higher costs.

The register over the last two years — Domestic institutions: +9.2 points over 8 quarters to 21.6%; Foreign institutions: −8.1 points over 8 quarters to 17.4%; Promoters: −1.4 points over 8 quarters to 53.2%.

Why the register moved: rotation — foreign institutions −8.1 points against domestic institutions +9.2 points over 8 quarters, with promoters −1.4 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Dr Lal Pathlabs Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Dr Lal Pathlabs Ltd trades at 57.0× P/E, mid-range by its own standards (55th percentile). Its long-run median P/E is 55.3×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 57.0× is mid-range by its own standards (55th percentile), against a long-run median of 55.3× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +3.4% against a +14.2% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the −1.5%/yr price move, ~+7.2%/yr came from earnings growth and ~−8.7 pp from the multiple (compressing); over 10y, of the +12.8%/yr price move, ~+14.9%/yr came from earnings growth and ~−2.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 26 August 2026 price, Dr Lal Pathlabs Ltd was paying for profit growth of about 28.4% a year. Profit itself has compounded 14.4% a year over the past 10 years. Today the market pays 57.0× P/E, the 55th percentile of its own 11-year range.

What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is above what this company has actually delivered.

How to hold this number: it is a reading of one day's price, taken on 26 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Dr Lal Pathlabs Ltd reads as topping out on its fundamental arc. Topping out — profit and EPS growth have decelerated hard (profit growth +44.9% at its peak → +5.0% latest) while ROCE still reads 27.6%. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.

4-Factor Sector Score

58.8/100 — rank 4 of 9 in Diagnostics · 100% evidence confidence

Dr Lal Pathlabs Ltd scores 58.8 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 4. Price leads the evidence: RS versus the benchmark is 23.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.

The four contributions add to the total exactly: 13.9 + 17.6 + 10.5 + 16.8 = 58.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Dr Lal Pathlabs Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

FY27 Radiology and Capex Scope Expanded · 24 July 2026. In Apr 2026, management guided FY27 capex at Rs. 100 crore - Rs. 120 crore and said the plan included 1 or 2 radiology centers. Jan 2026 described one Delhi NCR pilot with a second just starting, while the Jul 2026 call raised capex to Rs. 140-150 crore and targeted three to four centers; although management referenced Tier 2 pilots, it did not reconcile this materially larger scope with the earlier plan.

Mid-Teens FY27 Revenue Guidance Lacks Previously Stated Price Hike and M&A Enablers · 30 April 2026. In the Oct 2025 call, management explicitly framed reaching a 13-14% long-term revenue growth rate as requiring periodic price increases and M&A as additional catalysts above the 11-12% organic baseline, and the Jan 2026 call reinforced that any price increase was still 3-4 quarters away as a prerequisite before growth could meaningfully exceed 11-12%. The Apr 2026 call now guides FY27 revenue at 13-15% while simultaneously confirming that any price increase remains 'a few quarters away' and 'not immediately on the cards,' with no M&A announced and no explanation offered for what changed in the underlying growth driver equation.

Suburban Double-Digit Growth Promise Replaced by Vague Return to Growth Language · 30 April 2026. In the Oct 2025 call, management made a specific commitment that Suburban would 'come back to our original double-digit growth' by around Q4 FY26. The Apr 2026 call, covering Q4 FY26 results, only characterizes Suburban as having 'returned to growth' in the quarter, conspicuously omitting any confirmation of the double-digit recovery that was explicitly promised. The matter is further obscured by Suburban having been merged into the parent entity and no longer separately reported, making it impossible for investors to independently verify whether the stated target was actually achieved.

Radiology Significance Horizon Silently Extended From 2-3 Years to 4-5 Years · 30 April 2026. In the Oct 2025 call, management described the high-end radiology pilot as progressing 'robust' and committed to expanding to 'a few more centers' within FY26, signaling meaningful near-term momentum in the segment. The Jan 2026 call placed the horizon for radiology becoming a significant top-line contributor at 'not in the next 2-3 year scenario,' but the Apr 2026 call has now extended this to 'the next 4-5 years' while characterizing the overall plan as 'very slow and calibrated' - a material lengthening of the investment timeline with no explanation for what changed in management's assessment of the segment's trajectory.

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions